| Recruiting | Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers NCT07260708 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injecti NCT06649656 | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | Phase 1 |
| Recruiting | Psilocybin in Cancer Pain Study NCT06001749 | Yvan Beaussant, MD, MSci | Phase 2 |
| Recruiting | A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors NCT06413953 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers NCT05333276 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers NCT05380882 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Hepatic Impairment Study for Lorlatinib in Cancer Patients NCT03726333 | Pfizer | Phase 1 |
| Recruiting | Plasmodium Immunotherapy for Advanced Cancers NCT03375983 | CAS Lamvac Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the P NCT02801045 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | N/A |
| Completed | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair NCT02873975 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors NCT02478320 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies NCT02668770 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis NCT02623959 | M.D. Anderson Cancer Center | Phase 4 |
| Terminated | Sublingual Fentanyl for the Management of Breakthrough Pain NCT02514252 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea NCT02597478 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Terminated | Occupational Therapy in Palliative Care NCT02521194 | M.D. Anderson Cancer Center | N/A |
| Completed | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies NCT02571036 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Completed | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors NCT02561234 | Aeglea Biotherapeutics | Phase 1 / Phase 2 |
| Completed | Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain NCT02459964 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Perception of Palliative Care Encounter NCT02558257 | M.D. Anderson Cancer Center | — |
| Completed | Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion NCT02523378 | M.D. Anderson Cancer Center | N/A |
| Completed | Registry Study for Personalized Cancer Therapy NCT02508662 | M.D. Anderson Cancer Center | — |
| Completed | Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion NCT02498899 | M.D. Anderson Cancer Center | N/A |
| Completed | Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Interve NCT02422329 | M.D. Anderson Cancer Center | N/A |
| Completed | Cordotomy for Refractory Cancer Pain NCT02345629 | M.D. Anderson Cancer Center | N/A |
| Completed | Rational Therapeutics Based on Matched Tumor and Normal Tissue NCT02272595 | M.D. Anderson Cancer Center | — |
| Withdrawn | A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Corr NCT02193672 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis NCT01952847 | M.D. Anderson Cancer Center | Phase 3 |
| Recruiting | Personalized Oncogenomics (POG) Program of British Columbia NCT02155621 | British Columbia Cancer Agency | N/A |
| Completed | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies NCT02042989 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea NCT01856114 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Regorafenib and Cetuximab in Patients With Advanced Malignancy NCT02095054 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer NCT01949662 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | BiPAP-Vapotherm RCT NCT01518140 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma NCT01983969 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL) NCT01653717 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea NCT01832402 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ipilimumab and Lenalidomide in Advanced Cancer NCT01750983 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Dasatinib and Crizotinib in Advanced Cancer NCT01744652 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Dexamethasone Dyspnea Study NCT01670097 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib NCT01432119 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Study of Curcumin, Vorinostat, and Sorafenib NCT01608139 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Genomic Profiling Assay in Phase I NCT02437617 | M.D. Anderson Cancer Center | — |
| Completed | Study of Vemurafenib, Carboplatin, and Paclitaxel NCT01636622 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer NCT01548144 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Breakthrough Dyspnea Fentanyl Study in Cancer Patients NCT01515566 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide NCT01200004 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Temsirolimus in Combination With Metformin in Patients With Advanced Cancers NCT01529593 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Erlotinib in Combination With Pralatrexate in Advanced Malignancies NCT01532011 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers NCT01563302 | Ionis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | The Effects of Ginseng on Cancer-Related Fatigue NCT01375114 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients NCT01430572 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors NCT01454804 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) NCT01201694 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer NCT01389830 | M.D. Anderson Cancer Center | — |
| Terminated | The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer NCT01193530 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Completed | Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Sma NCT01277744 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tolvaptan in Hyponatremic Cancer Patients NCT01199198 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer NCT01266057 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surger NCT01259284 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Completed | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab NCT01213238 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patie NCT02160366 | M.D. Anderson Cancer Center | — |
| Completed | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxalipla NCT01183663 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Trientine and Carboplatin in Advanced Malignancies NCT01178112 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A First in Man Study of MABp1 in Patients With Advanced Cancers NCT01021072 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Lapatinib With Sirolimus or Metformin NCT01087983 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients NCT01003626 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | TTP607 in Refractory Solid Malignancies NCT00939172 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | HAI Abraxane With Gemcitabine and Bevacizumab NCT01057264 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Physician Perceptions About Parenteral Hydration in Latin America and Spain NCT01011140 | M.D. Anderson Cancer Center | — |
| Completed | Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study NCT01024166 | M.D. Anderson Cancer Center | — |
| Completed | High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer NCT00934128 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab NCT00941499 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing NCT00909207 | M.D. Anderson Cancer Center | — |
| Completed | Self Reported Deviations From Opioid Analgesic Prescription NCT00907192 | M.D. Anderson Cancer Center | — |
| Completed | An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status NCT00903734 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients NCT00877773 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Erlotinib in Combination With Cetuximab NCT00895362 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) NCT00836927 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol NCT00851032 | M.D. Anderson Cancer Center | — |
| Completed | Hepatic Arterial Infusion (HAI) of Abraxane NCT00732836 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers NCT00473720 | Yale University | Phase 1 |
| Completed | LY2275796 in Advanced Cancer NCT00903708 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | The Effects of Thalidomide on Symptom Clusters NCT00379353 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients NCT00208013 | China Medical University Hospital | — |
| Completed | Azacytidine and Valproic Acid in Patients With Advanced Cancers NCT00496444 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Stagi NCT00499382 | M.D. Anderson Cancer Center | — |